OBJECTIVE： To investigate the effects and safety of Compound musk injection combined with edaravone on coagulation and neurological function of patients with traumatic brain injury. METHODS： A total of 84 patients with traumatic brain injury in our hospital during Apr. 2015 to Apr. 2016 were divided into observation group and control group， with 42 cases in each group. Control group was given Edaravone injection 30 mg+0.9％ sodium chloride injection 100 mL， bid， ivgtt； observation group was additionally given Compound musk injection 20 mL+0.9％ sodium chloride injection 250 mL， qd， ivgtt. Both groups were treated for 4 weeks. NIHSS score， GCS score， the levels of NSE， CRP， PT， APTT and D-dimer， GOS score， the occurrence of ADR were compared between 2 groups before and after treatment. RESULTS： After treatment， NIHSS score of 2 groups decreased significantly， compared to before treatment； the observation group was significantly lower than the control group， with statistical significance （P＜0.05）. GCS score of 2 groups increased significantly， compared to before treatment； and the observation group was significantly higher than the control group， with statistical significance （P＜0.05）. The serum levels of NSE， CRP， PT， APTT and D-dimer in 2 groups decreased significantly， compared to before treatment； and the observation group was significantly lower than the control group， with statistical significance （P＜0.05）. GOS score of observation group was significantly higher than that of control group， with statistical significance （P＜0.05）. No obvious adverse reaction was found in 2 groups during treatment. CONCLUSIONS： Compound musk injection combined with edaravone can improve coagulation and neurological function of patients with traumatic brain injury， relieve traumatic brain injury and improve prognosis.